ROBERT J. SPIEGEL, M.D., FACP - Corporate Board Profile

GERON CORP

Filing Date	Source Excerpt
2011-03-28	Dr. Spiegel holds an M.D. from the University of Pennsylvania and a B.A. from Yale University.
2012-04-03	Dr. Spiegel holds a B.A. from Yale University and a M.D. from the University of Pennsylvania.
2013-04-05	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2014-04-04	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2015-04-03	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2016-04-01	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2017-03-24	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. He has served as Chief Medical Officer of PTC Therapeutics and held various academic and industry positions in oncology.
2018-03-30	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2019-04-22	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2020-04-14	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. The Board believes Dr. Spiegel’s extensive medical experience developing oncology products, his deep understanding of pharmaceutical research and development, and broad expertise in gaining regulatory approval for drug candidates, enhances the Board’s ability to critically assess the progress and potential of imetelstat, and qualifies Dr. Spiegel to serve as a director.
2021-03-22	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2022-03-22	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2023-04-12	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2024-03-27	Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
2025-04-08	Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the boards of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017, and RenovoRx, a clinical-stage oncology company, since April 2023. In the last five years, he has previously served as a director for Athenex, a biopharmaceutical company, from August 2020 to September 2023, and Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, from September 2018 to January 2025. From March 2011 to April 2016, Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009, after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.